| Inimai Rathinavel, MD | |
|
3504 S Lafountain St, Kokomo, IN 46902-3803 | |
| (765) 776-3600 | |
| Not Available |
| Full Name | Inimai Rathinavel |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 20 Years |
| Location | 3504 S Lafountain St, Kokomo, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972745354 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 50583 (Arizona) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 50583 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Howard Regional Health Inc. | Kokomo, IN | Hospital |
| Memorial Hospital | Logansport, IN | Hospital |
| Community Hospital East | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Physicians Of Indiana Inc | 1759416662 | 1319 |
News Archive
Deadly familial stomach and lobular breast cancers could be successfully treated at their earliest stages, or even prevented, by existing drugs that have been newly identified by cancer genetics researchers at New Zealand's University of Otago.
Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.
Neuroscientists at Lund University in Sweden have developed a new technology that engineers the shell of a virus to deliver gene therapy to the exact cell type in the body that needs to be treated. The researchers believe that the new technology can be likened to dramatically accelerating evolution from millions of years to weeks.
BeaconEquity.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company's lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.
› Verified 7 days ago
| Entity Name | Community Physicians Of Indiana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619105244 PECOS PAC ID: 1759416662 Enrollment ID: O20100317000717 |
News Archive
Deadly familial stomach and lobular breast cancers could be successfully treated at their earliest stages, or even prevented, by existing drugs that have been newly identified by cancer genetics researchers at New Zealand's University of Otago.
Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.
Neuroscientists at Lund University in Sweden have developed a new technology that engineers the shell of a virus to deliver gene therapy to the exact cell type in the body that needs to be treated. The researchers believe that the new technology can be likened to dramatically accelerating evolution from millions of years to weeks.
BeaconEquity.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company's lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Inimai Rathinavel, MD 6626 E 75th St Ste 500, Indianapolis, IN 46250-2890 Ph: () - | Inimai Rathinavel, MD 3504 S Lafountain St, Kokomo, IN 46902-3803 Ph: (765) 776-3600 |
News Archive
Deadly familial stomach and lobular breast cancers could be successfully treated at their earliest stages, or even prevented, by existing drugs that have been newly identified by cancer genetics researchers at New Zealand's University of Otago.
Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.
Neuroscientists at Lund University in Sweden have developed a new technology that engineers the shell of a virus to deliver gene therapy to the exact cell type in the body that needs to be treated. The researchers believe that the new technology can be likened to dramatically accelerating evolution from millions of years to weeks.
BeaconEquity.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company's lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.
› Verified 7 days ago
Leny Philip, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3118 S Lafountain St, Kokomo, IN 46902 Phone: 765-864-4160 Fax: 765-864-4166 | |
Dr. Alok Silodia, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2350 S Dixon Rd Ste 430, Kokomo, IN 46902 Phone: 765-453-1205 Fax: 765-453-6889 | |
Huan Cui, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1907 W Sycamore St, Kokomo, IN 46901 Phone: 765-456-5433 | |
Dr. Dawn Marie Sabau, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3508 S Lafountain St, Kokomo, IN 46902 Phone: 765-453-8181 Fax: 765-453-8565 | |
Julie B Tredemeyer, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3611 S Reed Rd Ste 103, Kokomo, IN 46902 Phone: 765-776-5500 | |
Dr. Imran Ahmed Sethi, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1907 W Sycamore St, Kokomo, IN 46901 Phone: 765-456-5847 | |
Karthik Rao Polsani, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3500 S Lafountain St, Kokomo, IN 46902 Phone: 765-776-3020 Fax: 775-453-8111 |